Human biodistribution and radiation dosimetry for the tau tracer [18F]Florzolotau in healthy subjects

Kun Ju Lin, Shao Yi Huang, Kuo Lun Huang, Chin Chang Huang, Ing Tsung Hsiao*

*Corresponding author for this work

Research output: Contribution to journalJournal Article peer-review

Abstract

Background: Tau pathology plays a crucial role in neurodegeneration diseases including Alzheimer’s disease (AD) and non-AD diseases such as progressive supranuclear palsy. Tau positron emission tomography (PET) is an in-vivo and non-invasive medical imaging technique for detecting and visualizing tau deposition within a human brain. In this work, we aim to investigate the biodistribution of the dosimetry in the whole body and various organs for the [18F]Florzolotau tau-PET tracer. A total of 12 healthy controls (HCs) were enrolled at Chang Gung Memorial Hospital. All subjects were injected with approximately 379.03 ± 7.03 MBq of [18F]Florzolotau intravenously, and a whole-body PET/CT scan was performed for each subject. For image processing, the VOI for each organ was delineated manually by using the PMOD 3.7 software. Then, the time-activity curve of each organ was acquired by optimally fitting an exponential uptake and clearance model using the least squares method implemented in OLINDA/EXM 2.1 software. The absorbed dose for each target organ and the effective dose were finally calculated. Results: From the biodistribution results, the elimination of [18F]Florzolotau is observed mainly from the liver to the intestine and partially through the kidneys. The highest organ-absorbed dose occurred in the right colon wall (255.83 μSv/MBq), and then in the small intestine (218.67 μSv/MBq), gallbladder wall (151.42 μSv/MBq), left colon wall (93.31 μSv/MBq), and liver (84.15 μSv/MBq). Based on the ICRP103, the final computed effective dose was 34.9 μSv/MBq with CV of 10.07%. Conclusions: The biodistribution study of [18F]Florzolotau demonstrated that the excretion of [18F]Florzolotau are mainly through the hepatobiliary and gastrointestinal pathways. Therefore, a routine injection of 370 MBq or 185 MBq of [18F]Florzolotau leads to an estimated effective dose of 12.92 or 6.46 mSv, and as a result, the radiation exposure to the whole-body and each organ remains within acceptable limits and adheres to established constraints. Trial registration : Retrospectively Registered at Clinicaltrials.gov (NCT03625128) on 12 July, 2018, https://clinicaltrials.gov/study/NCT03625128.

Original languageEnglish
Article number27
Pages (from-to)27
JournalEJNMMI Radiopharmacy and Chemistry
Volume9
Issue number1
DOIs
StatePublished - 02 04 2024

Bibliographical note

© 2024. The Author(s).

Keywords

  • Alzheimer’s disease
  • Biodistribution
  • Radiation dosimetry
  • Tau PET
  • [F]Florzolotau

Fingerprint

Dive into the research topics of 'Human biodistribution and radiation dosimetry for the tau tracer [18F]Florzolotau in healthy subjects'. Together they form a unique fingerprint.

Cite this